ERBB2 Emerges as a New Target for Colorectal Cancer

作者：Pectasides Eirini; Bass Adam J^*

来源：Cancer Discovery, 2015, 5(8): 799-801.

DOI：10.1158/2159-8290.CD-15-0730

ERBB2 mutations and amplifications are present in 7% of colorectal cancers. The presence of these alterations may be a marker of resistance to anti-EGFR therapy and, more importantly, could help identify patients who would benefit from ERBB2-directed therapy.

• 出版日期2015-8
• 单位MIT